Thiazolidinedione safety

Expert Opinion on Drug Safety

Volumn 11, Issue 4, 2012, Pages 565-579

  Kung, Jacqueline ^a   Henry, Robert R ^b  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Peroxisome proliferator activated receptor (PPAR) gamma agonists; Pioglitazone; Rosiglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; GEMFIBROZIL; INSULIN; METFORMIN; MIDAZOLAM; NIFEDIPINE; PIOGLITAZONE; PLACEBO; RIFAMPICIN; ROSIGLITAZONE; SULFONYLUREA; TRIMETHOPRIM; TROGLITAZONE; WARFARIN;

AREA UNDER THE CURVE; BLADDER CANCER; BLOOD CELL COUNT; BREAST FEEDING; CARDIOVASCULAR RISK; CHILD CARE; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG APPROVAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EDEMA; FRACTURE; GERIATRICS; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; LIVER DISEASE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MACULAR EDEMA; MYOCARDIAL INFARCTION; PPAR ALPHA; PPAR GAMMA; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84862886329     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.691963     Document Type: Review

References (101)

1. Norris S, Carson S, Roberts C. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: A meta-analysis. Curr Diabetes Rev 2007;3(2):127-40
2. Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 2007;356(24):2457-71
3. FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl. FDA Safety Announcement. U. S. Department of Health and Human Services. Washington,DC: U.S. Food and Drug Administration. 2011.Available from: http://www.fda.gov/Drugs/DrugSafety/ ucm255005.htm [Last accessed 20 February 2012]
4. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. Press release. London: European Medicines Agency. 2010.Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2010/09/ WC500096996.pdf [Last accessed 21 November 2010]
5. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011;34(4):916-22
6. Diamant M, Heine R. Thiazolidinediones in type 2 diabetes mellitus: Current clinical evidence. Drugs 2003;63(13):1373-405
7. Sears DD, Hsiao A, Ofrecio JM et al. Selective modulation of promoter recruitment and transcriptional activity of PPARgamma. Biochem Biophys Res Commun 2007;364(3):515-21
8. Psaty B, Furberg C. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;356(24):2522-4
9. Diamond G, Kaul S. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;357(9):938-9
10. Bracken M. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;357(9):937-8
11. Cardiovascular ischemic/thrombotic risks of the thiazolidinediones. Transcript for the July 30, 2007 Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Gaithersburg, Maryland: U. S. Food and Drug Administration Center for Drug Evaluation and Research. 2007.Available from: http://www.fda.gov/ohrms/dockets/ac/cder07. htm#EndocrinologicMetabolic [Last accessed 26 March 2011]
12. Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial. Lancet 2005;366(9493):1279-89
13. Rosen C. the rosiglitazone story-lessons from an FDA Advisory Committee meeting. N Engl J Med 2007;357(9):844-6
14. Singh S, Loke Y, Furberg C. Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 2007;298(10):1189-95
15. Lipscombe L, Gomes T, Levesque L, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298(22):2634-43
16. Graham D, Ouellet-Hellstrom R, MaCurdy T, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304(4):411-18
17. Winkelmayer W, Setoguchi S, Levin R, Solomon D. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008;168(21):2368-75
18. Juurlink D, Gomes T, Lipscombe L, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009;339:b2942
19. Brownstein J, Murphy S, Goldfine A, et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care 2010;33(3):526-31
20. Gerrits C, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007;16(10):1065-71
21. Ziyadeh N, McAfee A, Koro C, et al. the thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database. Clin Ther 2009;31(11):2665-77
22. Mannucci E, Monami M, Di Bari M, et al. Cardiac safety profile of rosiglitazone: A comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2010;143(2):135-40
23. McAfee A, Koro C, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007;16(7):711-25
24. Margolis D, Hoffstad O, Strom B. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008;17(8):753-9
25. Kahn S, Haffner S, Heise M, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
26. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368(9541):1096-105
27. BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360(24):2503-15
28. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59
29. Miller M. Relationship Between Glycemia Medications & Mortality in ACCORD. Presentation at the 68th Scientific Sessions of the American Diabetes Association. San Francisco, CA: 68th Scientific Sessions of the American Diabetes Association. 2008.Available from: http://professional. diabetes.org/presentations-details.aspx? session=3121 [Last accessed 26 March 2011]
30. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39
31. Cardiovascular safety of AVANDIA (rosiglitazone maleate). Transcript for the July 13-14 2010 Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Gaithersburg, MD: FDA Center for Drug Evaluation and Research. 2010.Available from: http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/drugs/ endocrinologicandmetabolic drugsadvisorycommittee/ucm191113 [Last accessed 26 March 2011]
32. Home P, Pocock S, Beck-Nielson H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009;373(9681):2125-35
33. Erdmann E, Dormandy J, Charbonnel B, et al. the effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49(17):1772-80
34. Rosen C. Revisiting the rosiglitazone story-lessons learned. N Engl J Med 2010;363(9):803-6
35. Nissen S, Wolski K. Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170(14):1191-201
36. Goldberg R, Kendall D, Deeg M, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28(7):1547-54
37. Actos (pioglitazone hydrochloride) package insert. Takeda Pharmaceuticals America, Inc.; Deerfield, IL: 2009
38. Erdmann E, Spanheimer R, Charbonnel B. Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: Results from the PROactive study (PROactive 20). J Diabetes 2010;2(3):212-20
39. Nesto R, Bell D, Bonow R, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003;108(23):2941-8
40. Guan Y, Hao C, Dea C. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11(8):861-6
41. Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004;89(3):1140-5
42. Fukunaga Y, Itoh H, Doi K, et al. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis 2001;158(1):113-19
43. Baba T, Shimada K, Neugebauer S, et al. the oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 2001;24(5):953-4
44. Dailey G, Noor M, Park J, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial. Am J Med 2004;116(4):223-9
45. Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab 2007;9(4):512-20
46. Schernthaner G, Matthews D, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial. J Clin Endocrinol Metab 2004;89(12):6068-76
47. Mattoo V, Eckland D, Widel M. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005;27(5):554-67
48. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. the Pioglitazone 001 Study Group. Diabetes Care 2000;23(11):1605-11
49. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87(6):2784-91
50. Smith S, De Jonge L, Volaufova J. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism 2005;54(1):24-32
51. Doehner W, Erdmann E, Cairns Ret al. Cairns R, et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular comorbidity: An analysis of the PROactive study population. Int J Cardiol 2011;published online 29 October 2011, doi: 10.1016/j.ijcard.2011.09.039.
52. Rosenblatt S, Miskin B, Glazer N, et al. the impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12(5):413-23
53. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003;25(4):1074-95
54. Derosa G, Cicero A, D'Angelo A. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: A multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006;28(5):679-88
55. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn A. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive. Drug Saf 2009;32(3):187-202
56. Risque de cancer de la vessie chez les personnes diabetiques traitees par pioglitazone en France : une etude de cohorte sur les donnees du SNIIRAM et du PMSI. France: Caisse National d'Assurance Maladie. 2011. Available from: http://www.afssaps.fr/var/afssaps-site/storage/original/application/ b42a6bf9a1b63c3dbec7388d3914687b. pdf [Last accessed 4 December 2011]
57. Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. FDA Drug Safety Communication. U.S. Department of Health and Human Services News. Washington, DC: U.S. Food and Drug Administration. 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm [Last accessed 4 December 2011]
58. Soroceanu M, Miao D, Bai X, et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004;183(1):203-16
59. Rzonca S, Suva L, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145(1):401-6
60. Ali A, Weinstein R, Stewart S, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146(3):1226-35
61. Loke Y, Singh S, Furberg C. Long-term use of thiazolidinediones and fractures in type 2 diabetes: A meta-analysis. CMAJ 2009;180(1):32-9
62. Short R. Fracture risk is a class effect of glitazones. BMJ 2007;334(7593):551
63. Meymeh R, Wooltorton E. Diabetes drug pioglitazone (Actos): Risk of fracture. CMAJ 2007;177(7):723-4
64. Floyd J, Barbehenn E, Lurie P, Wolfe S. Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf 2009;18(12):1238-43
65. Belcher G, Lambert C, Edwards G, et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2005;70(1):53-62
66. Tolman K, Freston J, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: Results from a 3-year, randomized, comparator-controlled study. Drug Saf 2009;32(9):787-800
67. Ryan E, Han D, Ramsay R, et al. Diabetic macular edema associated with glitazone use. Retina 2006;25(5):562-70
68. Fong D, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009;147(4):583-6
69. Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther 2007;82(3):275-81
70. Gimble J, Robinson C, Wu X, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996;50(5):1087-94
71. Hayashi Y, Miyachi N, Takeuchi T, et al. Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile. Diabetes Obes Metab 2003;5(1):58-65
72. Potential Signals of Serious Risks/New Safety Information Identified by the Adverse Event Reporting System (AERS) between July - September 2010. Adverse Event Reporting System Quarterly Report. Washington, DC: U.S. Food and Drug Administration. 2010. Available from: http://www.fda.gov/drugs/ guidancecomplianceregulatory information/surveillance/adversedrugeffects/ ucm237585.htm [Last accessed 26 March 2011]
73. Rajagopalan R, Perez A, Ye Z, et al. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Drugs Aging 2004;21(4):259-71
74. Rajagopalan R, Xu Y, Abbadessa M. the effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: A post hoc analysis of four randomized trials. Am J Geriatr Pharmacother 2006;4(2):123-33
75. Zdravkovic V, Hamilton J, Daneman D, Cummings E. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J Pediatr 2006;149(6):845-9
76. Chan L, Yeung J, Lau T. Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertil Steril 2005;83(4):955-8
77. Feig D, Briggs G, Koren G. Oral antidiabetic agents in pregnancy and lactation: A paradigm shift? Ann Pharmacother 2007;41(7):1174-80
78. Ota H, Goto T, Yoshioka T, Ohyama N. Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril 2008;90(3):709-13
79. Budde K, Neumayer H, Fritsche L, et al. the pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 2003;55(4):368-74
80. Manley H, Allcock N. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003;23(7):861-5
81. Abe M, Okada K, Maruyama T, et al. Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Expert Opin Pharmacother 2010;11(10):1611-20
82. Abe M, Kikuchi F, Okada K, et al. Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis. Diabetes Res Clin Pract 2008;80(3):432-8
83. Jaakkola T, Laitila J, Neuvonen P, Backman J. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006;99(1):44-51
84. Hoffmann T, Parker D, Buch H, Balusu P. Suspected suppression of the INR by thiazolidinediones: Interaction between warfarin and TZDs. Ann Pharmacother 2006;40(5):994-6
85. Jaakkola T, Backman J, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006;61(1):70-8
86. Jaakkola T, Backman J, Neuvonen M, Neuvonen P. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005;77(5):404-14
87. Deng L, Wang F, Li H. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005;61(11):831-6
88. Tornio A, Niemi M, Neuvonen P, Backman J. Trimethoprim and the CYP2C8.*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008;36(1):73-80
89. Rodbard H, Blonde L, Braithwaite S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1):1-68
90. Nathan D, Buse J, Davidson M. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203
91. Olefsky J. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000;106(4):467-72
92. Doshi L, Brahma M, Bahirat U, et al. Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. Expert Opin Investig Drugs 2010;19(4):489-512
93. Choi J, Banks A, Estall J, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010;466(7305):451-6
94. Acton Jr, Black R, Jones A, et al. Benzoyl 2-methyl indoles as selective PPARgamma modulators. Bioorg Med Chem Lett 2005;15(2):357-62
95. Houtkooper R, Auwerx J. Obesity: new life for antidiabetic drugs. Nature 2010;466(7305):443-4
96. Long GG, Reynolds VL, Lopez-Martinez A, et al. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol 2008;36:218-31
97. Chang F, Jaber LA, Berlie HD, O'Connell MBet al. Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 2007;41(6):973-83
98. Nissen SE, Wolski K, , Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294(20):2581-6
99. Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study. Lancet 2009;374(9684):126-35
100. Herz M, Gaspari F, Perico N, et al. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Int J Cardiol 2011;151(2):136-42
101. A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus. ClinicalTrials.gov Registry. Washington, DC: National Institutes of Health. 2011.Available from: http://clinicaltrials. gov/ct2/show/study/NCT01042769? term=aleglitazar &rank=6&show-locs= Y#locn [Last accessed 10 December 2011]